Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was $19.30 for the day, up 0.16% from the previous closing price of $19.27. In other words, the price has increased by $0.16 from its previous closing price. On the day, 1.6 million shares were traded. SNDX stock price reached its highest trading level at $20.37 during the session, while it also had its lowest trading level at $19.29.
Ratios:
Our analysis of SNDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.93 and its Current Ratio is at 8.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Scotiabank on January 31, 2024, Downgraded its rating to Sector Perform and sets its target price to $23 from $36 previously.
On December 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $45.
On October 25, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.BofA Securities initiated its Buy rating on October 25, 2023, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 09 ’23 when Morrison Briggs sold 52,855 shares for $18.27 per share. The transaction valued at 965,402 led to the insider holds 17,836 shares of the business.
Meury William sold 83,000 shares of SNDX for $1,697,810 on Aug 02 ’23. The Director now owns 48,000 shares after completing the transaction at $20.46 per share. On Jul 10 ’23, another insider, Morrison Briggs, who serves as the Director of the company, sold 52,855 shares for $20.40 each. As a result, the insider received 1,078,068 and left with 17,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1640251008 and an Enterprise Value of 1198477312.
Stock Price History:
Over the past 52 weeks, SNDX has reached a high of $25.34, while it has fallen to a 52-week low of $11.22. The 50-Day Moving Average of the stock is -10.65%, while the 200-Day Moving Average is calculated to be 0.74%.
Shares Statistics:
SNDX traded an average of 1.06M shares per day over the past three months and 1081650 shares per day over the past ten days. A total of 84.83M shares are outstanding, with a floating share count of 80.06M. Insiders hold about 5.80% of the company’s shares, while institutions hold 101.48% stake in the company. Shares short for SNDX as of 1715731200 were 10029116 with a Short Ratio of 9.50, compared to 1713139200 on 9603385. Therefore, it implies a Short% of Shares Outstanding of 10029116 and a Short% of Float of 11.8999995.
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of Syndax Pharmaceuticals Inc (SNDX) in the stock market.On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.88 and a low estimate of -$0.97, while EPS last year was -$0.64. The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.64 and low estimates of -$1.14.
Analysts are recommending an EPS of between -$3.06 and -$4.03 for the fiscal current year, implying an average EPS of -$3.62. EPS for the following year is -$2.97, with 12.0 analysts recommending between -$1.17 and -$3.91.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $106.75M in the next fiscal year. The high estimate is $195.85M and the low estimate is $68.1M.
